Skip to main content
. 2021 Sep 24;13(10):1550. doi: 10.3390/pharmaceutics13101550

Figure 7.

Figure 7

The chondrogenic effects of the DCECM, Mg-BGNs-1/DCECM and Mg-BGNs-2/DCECM scaffolds: (A) General scheme of the in vitro induction of chondrogenesis in BMSC pellets treated with DCECM, Mg-BGNs-1/DCECM and Mg-BGNs-2/DCECM scaffolds; (B) The gross observation of the pellets treated with DCECM, Mg-BGNs-1/DCECM and Mg-BGNs-2/DCECM scaffolds for 21 days; (C) HE staining of the pellets; (D) AB staining of the pellets; (E) collagen II staining of the pellets; (F) GAG normalized by DNA content of the pellets; data are expressed as mean ± standard deviation (n = 3; * p < 0.05, ** p < 0.01). (G–J), RT-PCR of SOX 9 (G); Collagen II (H); aggrecan (I); and Collagen I (J) from BMSC pellets treated with DCECM, Mg-BGNs-1/DCECM and Mg-BGNs-2/DCECM scaffolds for 21 days. Data are expressed as mean ± standard deviation (n = 3; * p < 0.05, ** p < 0.01).